πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 49 of 173

  1. US 10723777

    Peptide having anti-obesity and anti-diabetes efficacy and use thereof

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10723718

    Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10722523

    Chemoimmunotherapy for epithelial cancer

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10722475

    Stealth nanocapsules for protein delivery

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10722540

    Microfluidic device and method for shear stress-induced transformation of cells

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10723764

    Anti-microbial peptides and methods of use thereof

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10724026

    Engineered primate L-methioninase for therapeutic purposes

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10723778

    Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10723784

    Compositions and methods for preparing a subject for organ or non-organ implantation

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10722550

    Compositions and methods for the treatment of fungal infections

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10722573

    Compositions for stimulation of mammalian innate immune resistance to pathogens

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10723737

    Compositions and methods for treating neurodegenerative diseases and cardiomyopathy

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10716798

    Compositions and methods for tranquilizing heart muscle

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10717799

    Copolymers as excipients for effective solubilization of poorly water-soluble substances from solid mixtures

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10716856

    Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10718778

    Compositions and methods for detecting protein sulfenylation

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10717981

    Therapeutic compositions and methods of making and using the same

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10709812

    Biodegradable hydrogel for tissue expansion

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10709758

    Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10709739

    Method for chemoselection

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10711312

    Methods for immunotherapy-based treatment and assessment of cancer

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10709705

    Aminopyrimidines as ALK inhibitors

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10709733

    Nonsurgical techniques for restoring tooth enamel

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10709813

    Solubilization of antigen components for removal from tissues

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10711292

    Method for promoting the synthesis of collagen and proteoglycan in chondrocytes

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10703805

    Molecular imprinting of West Nile antibodies with physiological pH matching

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10702506

    Small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10703721

    Caffeic acid derivatives and uses thereof

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10702473

    Liposome formulation for delivery of Wnt signal pathway inhibitor

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10702498

    MU opioid receptor modulators

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10702474

    Fusogenic liposome-coated porous silicon nanoparticles

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10702532

    Nucleotide analogs

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10703698

    Compounds which activate estrogen receptors and compositions and methods of using the same

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10696710

    Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10695279

    Peptide having skin-whitening activity and use thereof

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10695325

    Compounds and methods for treating an epileptic disorder

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10689392

    Anti-cancer compounds targeting ral GTPases and methods of using the same

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10688181

    Cancer treatment combinations

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10687520

    Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10689595

    Synthesis and use of omega-hydroxylated polyunsaturated fatty acids

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10688160

    Enzymes and methods for cleaving N-glycans from glycoproteins

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10688453

    System and method for droplet formation and manipulation using ferrofluids

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10688285

    Spinal subpial gene delivery system

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10688080

    Compositions, methods of use, and methods of treatment

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10688203

    Methods of performing brachytherapy

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10683347

    Treatment of cancer using anti-TGF-Ξ² and anti-PD-1 antibodies

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10682310

    Therapeutic compounds and formulations for intranasal delivery

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10682388

    Targeting of PELP1 in cancer therapy

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.